Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY
BCDx is a urine-based multi-omic assay for early cancer recurrence detection in patients with a history of bladder cancer. This prospective, blinded study evaluates its efficacy in detecting recurrent NMIBC, offering a noninvasive monitoring solution.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients 18 Years and older
• Patients who have been diagnosed with incident or recurrent NMIBC within the past 2 years and undergoing standard of care/routine monitoring cystoscopy.
• Patients who are able to provide legally effective informed consent.
• Patients who are able to provide minimum 30mL of voided urine.
Locations
United States
Arkansas
Arkansas Urology Research Center
RECRUITING
Little Rock
Indiana
Indiana University School of Medicine
RECRUITING
Indianapolis
Missouri
Washington University
RECRUITING
St Louis
Contact Information
Primary
Thakshila Liyanage, PhD
thakshila@earlyisgood.com
(317) 941-6953
Time Frame
Start Date: 2023-07-26
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 500
Related Therapeutic Areas
Sponsors
Leads: Early is Good Inc.